Literature DB >> 1849159

The natural history of ultraviolet radiation-induced herpes simplex labialis and response to therapy with peroral and topical formulations of acyclovir.

S L Spruance1, D J Freeman, J C Stewart, M B McKeough, L G Wenerstrom, G G Krueger, M W Piepkorn, W G Stroop, N H Rowe.   

Abstract

The lips of 196 patients with a history of sun-induced herpes labialis were exposed to experimental ultraviolet radiation (UVR) and treated with acyclovir (ACV) or placebo at different times and by different routes. Of 98 placebo recipients, 39 (40%) developed 43 lesions inside or within 10 mm of the irradiated zone. The temporal distribution of lesions was bimodal. 11 (26%) occurring within 48 h (immediate) and 32 (72%) 2-7 days after UVR exposure (delayed). Prophylactic peroral ACV begun 7 days before or 5 min after UVR prevented the development of the delayed but not the immediate lesions (P less than .001). When peroral ACV was started 48 h after UVR, delayed lesions developed but were less severe (P = .01-.05). Prophylactic topical ACV begun 5 min after UVR did not reduce lesion frequency or severity. ACV therapy can be efficacious, but some rapidly developing lesions are unresponsive to treatment. This suggests that more than one process may contribute to the pathogenesis of herpes labialis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849159     DOI: 10.1093/infdis/163.4.728

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

Review 1.  Treatment and prevention of herpes labialis.

Authors:  Wim Opstelten; Arie Knuistingh Neven; Just Eekhof
Journal:  Can Fam Physician       Date:  2008-12       Impact factor: 3.275

Review 2.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

Review 3.  Herpes labialis.

Authors:  Graham Worrall
Journal:  BMJ Clin Evid       Date:  2009-09-23

4.  Effect of foscarnet cream on experimental UV radiation-induced herpes labialis.

Authors:  D I Bernstein; C J Schleupner; T G Evans; D A Blumberg; Y Bryson; K Grafford; P Broberg; S Martin-Munley; S L Spruance
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

5.  Acyclovir in recurrent herpes labialis.

Authors:  G Worrall
Journal:  BMJ       Date:  1996-01-06

6.  Correlation between detection of herpes simplex virus in oral secretions by PCR and susceptibility to experimental UV radiation-induced herpes labialis.

Authors:  J D Kriesel; P L Pisani; M B McKeough; J R Baringer; S L Spruance
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

7.  Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy.

Authors:  P A Asbell
Journal:  Trans Am Ophthalmol Soc       Date:  2000

8.  Spontaneous reactivation of herpes simplex virus type 1 in latently infected murine sensory ganglia.

Authors:  Todd P Margolis; Fred L Elfman; David Leib; Nazzy Pakpour; Kathleen Apakupakul; Yumi Imai; Cindy Voytek
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

Review 9.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

10.  Double-blind, randomized, placebo-controlled study of topical 5% acyclovir-1% hydrocortisone cream (ME-609) for treatment of UV radiation-induced herpes labialis.

Authors:  T G Evans; D I Bernstein; G W Raborn; J Harmenberg; J Kowalski; S L Spruance
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.